Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI

• Status: Completed
• Trial end date: 2019-07-03
• Target enrollment: 0
• Participant gender: All

Summary

The innovative drug XC221 is planned for use in treatment of acute respiratory viral infections in a double-blind, randomized, placebo-controlled, comparative multicenter study assessing the safety, tolerability and efficacy of XC221 at a dose of 200 mg per day in patients with uncomplicated influenza or other acute respiratory viral infections during the 3-days treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PHARMENTERPRISES LLC
• Collaborator: RSV Therapeutics LLC

Criteria

Inclusion Criteria:

1. Both sexes aged 18 years and older.

2. Clinically diagnosed influenza or ARVI mild or moderate severity.

3. Patient's body temperature ≥37.5ºС and at least 1 symptom from Modified Jackson Scale estimated more than 2 points.

4. Uncomplicated course of influenza or ARVI based on clinical estimations.

5. The first 36 hours from the beginning of symptoms of influenza or ARVI.

6. Women of reproductive age (who are not in menopause and who have not undergone surgical sterilization) and men who have sexual activity should use a reliable method of contraception (acceptable methods of contraception in this study are: intrauterine devices, oral contraceptives, contraceptive patch, long-acting injectable contraceptives, a double barrier method (condom and diaphragm with spermicide) throughout the study period.

7. Compliance with the treatment regimen, visits and laboratory examinations provided by the protocol.

8. Signed Informed Consent Form.

Exclusion Criteria:

1. Complications of influenza or ARVI (including the presence / development of bacterial infection).

2. The need for inpatient treatment of influenza and ARVI.

3. Hypersensitivity to excipients of the drug XC221 or placebo.

4. Antiviral medications 7 days prior to screening (antiviral agents, interferons and interferon inducers, drugs that have immunomodulating action) or anti-infective agents of systemic or local action.

5. Severe infection with signs of cardiovascular insufficiency development and other manifestations of infectious-toxic shock, as well as with the presence of neuroinfection syndrome (encephalic and meningoencephalic reactions, polyradiculoneuritis, neuritis).

6. Signs of of viral pneumonia symptoms (the presence of two or more of the following symptoms): dyspnea, chest pain when coughing, systemic cyanosis, dullness of percussion sound with a symmetrical evaluation of the upper and lower sections of the lungs).

7. Infectious diseases during the last week before including into the study.

8. Bronchial asthma, COPD, pulmonary emphysema in history.

9. History of increased convulsive activity.

10. Severe, decompensated or unstable somatic diseases (any diseases or conditions that are life-threatening or may worsen the patient's prognosis, and make him/her ineligible for the clinical study).

11. History of oncological diseases, HIV, tuberculosis.

12. Drug or alcohol abuse.

13. Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

14. Participation in any other clinical trial in the last 90 days.

15. Pregnancy or lactation.

16. Military or prison populations.

17. Impossibility or inability to comply with the study procedures.

18. A member of the investigator's family or other person interested in the results of the study.

19. Deviations from laboratory standards, which prevent the inclusion of the patient in the study according to the Investigator.

20. A history of kidney failure.